Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares

Regeneron Pharmaceuticals, Inc. REGN today announced that it intends, subject to market conditions, to offer 4,500,000 shares of its common stock pursuant to an underwriting agreement with Citi acting as the sole bookrunner. The Company expects to use the net proceeds from the sale of the shares for general corporate purposes. Closing of the offering is expected to occur on or about October 11, 2010, subject to customary closing conditions. In addition, the Company intends to grant the underwriter a 30-day option to purchase up to an additional 675,000 shares of common stock to cover over-allotments, if any.